Work

Donanemab dans la maladie d’Alzheimer symptomatique précoce : informations supplémentaires issues de l’étude TRAILBLAZER-ALZ 2 et le risque d’ARIA

Year: 2025

Type: article

Source: Revue Neurologique

DOI: 10.1016/j.neurol.2025.01.144

Authors: Steven Greenberg, Paul Ardayfio, Chakib Battioui, Cynthia Evans, Jennifer Zimmer, Pauline Lapalus, John Sims

Institutions: Harvard University, Eli Lilly (United States)

Language: French

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4408570109

FWCI:

Cites:

Cited by:

Related to: 10